Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ian G. Kerr"'
Autor:
C. Cripps, Amit M. Oza, Malcolm J. Moore, Rakesh Goel, Jean A. Maroun, Helene Dulude, Ian G. Kerr, Colin Germond, Georg A. Bjarnason, J. Skillings, Edmee Franssen, S. Fine
Publikováno v:
American Journal of Clinical Oncology. 21:537-542
The objective of this phase I-II study was to determine the efficacy and toxicity of combination chemotherapy with 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and oral etoposide (FLAME) in patients with measurable unresectable or metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c3e092938472162f81b9a0a72d977f1
https://doi.org/10.1097/00000421-199812000-00001
https://doi.org/10.1097/00000421-199812000-00001
Autor:
Hoffmann W, Ian G. Kerr, Thuerlimann B, C. Erlichman, Hans-Joachim Schmoll, S. Fine, B. Gustavsson, C. Gorg, P. Preusser
Publikováno v:
American Journal of Clinical Oncology. 19:26-31
We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b74402d458c1fe845a2b5de966d2b048
https://doi.org/10.1097/00000421-199602000-00006
https://doi.org/10.1097/00000421-199602000-00006
Autor:
Nicoletta Colombo, M.E.L. van der Burg, Luca Gianni, James Myles, Jan B. Vermorken, Kenneth D. Swenerton, Ian G. Kerr, W.W. ten Bokkel Huinink, Elizabeth Eisenhauer, K Buser
Publikováno v:
Journal of Clinical Oncology. 12:2654-2666
PURPOSE Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer agent with activity in a number of human tumors, including epithelial ovarian cancer. In nonrandomized trials, doses studied have ranged from 135 mg/m2 to 250 mg/m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1726d27977fd52194a04210e5e441820
https://doi.org/10.1200/jco.1994.12.12.2654
https://doi.org/10.1200/jco.1994.12.12.2654
Publikováno v:
Journal of Palliative Care. 6:51-59
Morphine and hydromorphone infusions of 6 or more (average 25.75) days in duration were used with increasing frequency (up to 7%) by our oncology inpatients. Eighty-six percent of the 135 inpatients we reviewed realized good pain control with dose ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ce34239600679e1434b5611ada2e89e
https://doi.org/10.1177/082585979000600209
https://doi.org/10.1177/082585979000600209
Autor:
Merrill J. Egorin, Paula M. Fracasso, Ian G. Kerr, Manuel Litchman, Malcolm J. Moore, Ellen Warner, Saul E. Rivkin, Amita Patnaik, Michael Michael, Lillian L. Siu, Amit M. Oza
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(21)
PURPOSE: To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 weeks with the oral semisynthetic cyclosporine analog valspodar (PSC 833)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d593f1ab2d4622dfc7c51c3e3a52053a
https://pubmed.ncbi.nlm.nih.gov/11054441
https://pubmed.ncbi.nlm.nih.gov/11054441
Autor:
Ian G. Kerr
Publikováno v:
Anti-cancer drugs. 6
Cancer is a common cause of death in our society and associated pain is prevalent in cancer patients. Despite this, pain is often not treated optimally. Although education (patient and caregiver) might improve the situation, many difficulties remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d12019f6a67ff4a98290905c2d82a9b
https://pubmed.ncbi.nlm.nih.gov/7606032
https://pubmed.ncbi.nlm.nih.gov/7606032
Autor:
S.J. Soldin, Peter S. Bunting, Jake J. Thiessen, Robert W. Hardy, Ian G. Kerr, Charles Erlichman, Malcolm J. Moore
Publikováno v:
Cancer chemotherapy and pharmacology. 33(6)
A total of 23 women with stage II breast cancer receiving adjuvant cyclophosphamide, methotrexate and 5-fluorouracil had detailed pharmacokinetic monitoring performed on the first and third courses of therapy. The area under the concentration time cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca510ec3f91c80f13a904d50633c8949
https://pubmed.ncbi.nlm.nih.gov/8137456
https://pubmed.ncbi.nlm.nih.gov/8137456
Autor:
Hans-Joachim Schmoll, W. Hoffman, C. Gorg, Ian G. Kerr, P. Preusser, C. Erlichman, S. Fine, H.-J. Senn, B. Gustavsson
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9781461360605
The mainstay of treatment for patients with metastatic colorectal cancer is chemotherapy with the combination of 5-Fluorouracil (5FU) and Leucovorin (LV) 1. This treatment has resulted in a response rate of 23% compared to 11% for 5FU in nine randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b92f4f723a293cfd6be3944f4605256
https://doi.org/10.1007/978-1-4615-2488-5_9
https://doi.org/10.1007/978-1-4615-2488-5_9
Publikováno v:
Journal of pain and symptom management. 6(6)
Nausea affects from 40% to 70% of cancer patients who received narcotics to manage their pain. This occurs more frequently when they are ambulatory than when they are recumbent and may be the result of narcotic-enhanced labyrinthine sensitivity to mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efebcc73b7b29a87c8214ad1ab07eda
https://pubmed.ncbi.nlm.nih.gov/1880439
https://pubmed.ncbi.nlm.nih.gov/1880439
Publikováno v:
Journal of clinical epidemiology. 44(3)
We conducted a retrospective, non-randomized, cost-minimization study, from the perspective of the Ministry of Health, to compare the cost of managing cancer patients who required narcotic infusions, in hospital and at home. Our medical costs average
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9337cd0aaa85c285bb28de3a433ab865
https://pubmed.ncbi.nlm.nih.gov/1705580
https://pubmed.ncbi.nlm.nih.gov/1705580